3 completed, 2 active not recruiting, 1 recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
| Phase 1 | 2 | Completed 2 |
Follow Recurrent Esophageal Carcinoma: new trials by email Literature Review of Recurrent Esophageal Carcinoma trials Research Report on Recurrent Esophageal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
| Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Epacadostat, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Completed | George Albert Fisher | 3 | 2017-09-13 | 2024-01-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel - Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2010-09-21 | 2026-09-10 |
Esophageal Neoplasms (6) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Breast Neoplasms (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Astrocytoma (1)
Digestive System Diseases (6) · Digestive System Neoplasms (6) · Esophageal Diseases (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Head and Neck Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Stomach Diseases (4) · Adenocarcinoma (3) · Colonic Diseases (3) · Female Urogenital Diseases (3)
Specimen Handling (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Biopsy (1) · Blood Specimen Collection (1) · CT-P6 (1) · Crizotinib (1) · Dasatinib (1) · Disulfides (1) · GSK2636771 (1) · HhAntag691 (1) · Immunoglobulin G (1)
National Cancer Institute (NCI) (3) · George Albert Fisher (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (6) · Guam (1) · Puerto Rico (1)
Dev Mukhopadhyay, PhD (1) · George A Fisher, MD (1) · Keith T Flaherty (1) · Kunle Odunsi (1) · Michael Cecchini (1) · Steven J Cohen (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37104870, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40132910, PMID 40791544, PMID 40865033, PMID 41066729, PMID 41484629
U10CA180820 (2), P30CA016056 (1), R01CA158318 (1), U10CA021115 (1), U24CA196172 (1), UM1CA186689 (1)